ERBB2 and breast carcinoma: Similarly, breast cancer subtypes—HER2-positive, Luminal A/B, and Basal-like—require distinct biomarker panels (HER2, estrogen receptor (ER), and progesterone receptor (PR)) to guide treatment selection196,197.